Mairs RJ - Search Results

1

Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.

Mairs RJ, Boyd M. Mairs RJ, et al. Nucl Med Biol. 2008 Aug;35 Suppl 1:S9-20. doi: 10.1016/j.nucmedbio.2008.04.008. Nucl Med Biol. 2008. PMID: 18707637 Review.

2

Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors.

Mairs RJ, Boyd M. Mairs RJ, et al. Semin Nucl Med. 2011 Sep;41(5):334-44. doi: 10.1053/j.semnuclmed.2011.03.004. Semin Nucl Med. 2011. PMID: 21803183 Review.

3

Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.

Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, Board J, George RE, Ellershaw C, Pearson AD, Lunec J, Montaldo PG, Ponzoni M, van Eck-Smit BL, Hoefnagel CA, van den Brug MD, Tytgat GA, Caron HN. Carlin S, et al. Among authors: mairs rj. Clin Cancer Res. 2003 Aug 15;9(9):3338-44. Clin Cancer Res. 2003. PMID: 12960120

4

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.

Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Gaze MN, et al. Among authors: mairs rj. Cancer Biother Radiopharm. 2005 Apr;20(2):195-9. doi: 10.1089/cbr.2005.20.195. Cancer Biother Radiopharm. 2005. PMID: 15869455

5

Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy.

Rae C, Haberkorn U, Babich JW, Mairs RJ. Rae C, et al. Among authors: mairs rj. Radiat Res. 2015 Nov;184(5):482-93. doi: 10.1667/RR14173.1. Epub 2015 Oct 20. Radiat Res. 2015. PMID: 26484401

6

Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.

Tesson M, Rae C, Nixon C, Babich JW, Mairs RJ. Tesson M, et al. Among authors: mairs rj. J Pharm Pharmacol. 2016 Jul;68(7):912-21. doi: 10.1111/jphp.12558. Epub 2016 May 3. J Pharm Pharmacol. 2016. PMID: 27139157 Free PMC article.

7

Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells.

Rae C, Mairs RJ. Rae C, et al. Among authors: mairs rj. Int J Radiat Biol. 2017 Feb;93(2):194-203. doi: 10.1080/09553002.2017.1231946. Epub 2016 Oct 3. Int J Radiat Biol. 2017. PMID: 27600766

8

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.

Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ. Nile DL, et al. Among authors: mairs rj. BMC Cancer. 2016 Aug 11;16:621. doi: 10.1186/s12885-016-2656-8. BMC Cancer. 2016. PMID: 27515310 Free PMC article.

9

Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.

Rae C, Tesson M, Babich JW, Boyd M, Mairs RJ. Rae C, et al. Among authors: mairs rj. EJNMMI Res. 2013 Nov 13;3(1):73. doi: 10.1186/2191-219X-3-73. EJNMMI Res. 2013. PMID: 24219987 Free PMC article.

10

In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.

Sorensen A, Mairs RJ, Braidwood L, Joyce C, Conner J, Pimlott S, Brown M, Boyd M. Sorensen A, et al. Among authors: mairs rj. J Nucl Med. 2012 Apr;53(4):647-54. doi: 10.2967/jnumed.111.090886. Epub 2012 Mar 13. J Nucl Med. 2012. PMID: 22414636

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results